Introduction
Precise cancer treatment relies on maximizing the toxic effect of anticancer drugs to tumor sites while minimizing the side effects to normal regions. 1 To date, theranostic prodrug systems with integrated diagnostic and therapeutic functions have been developed as promising tools in precision cancer medicine.
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These systems are particularly useful for cancer therapy, providing activated release of drugs and concomitant in situ drug tracking capability in response to endogenous stimuli (including pH, 3 hypoxia, 4 increased glutathione levels, 5 elevated oxidative stress, 6 and specic enzyme overexpression 7 ) and/or exogenous stimuli (including light 8 and heat
9
). However, concurrent events including the diagnostic and therapeutic capabilities of the available theranostic prodrugs do not allow for diagnosis-directed on-demand therapy. Thus the search for image-guided prodrugs, in which the tumor can be diagnosed and the subsequent diagnosis controlled on-demand drug administration to the detected region could be realized, is ongoing but remains challenging.
Photodynamic therapy (PDT) is a potent noninvasive therapeutic modality for a variety of cancers.
10 PDT treatment utilizes a photosensitizer that serves as a light-sensitive drug to generate cytotoxic ROS upon light irradiation for disrupting cellular function and killing the cells in the exposed area.
11 As light can provide the advantages of a noninvasiveness mode and precise spatiotemporal controllability, light-sensitive photosensitizers will cause less treatment-related toxicity and fewer side effects on adjacent normal tissues when compared with conventional chemotherapeutic reagents.
12 Thus, a theranostic prodrug that integrates a diagnostic probe and a light-sensitive drug would be rather attractive because the tumor can be monitored and then diagnosis can precisely guide the ondemand light exposure to the detected region while leaving normal tissues untouched. Notably, the precise spatial location of the PDT agent and the timing of implementation of the light illumination are critical to maximize the therapeutic effect.
Herein, in this work, we reported a theranostic prodrug for activatable near-infrared emission-guided on-demand administration of photodynamic anticancer therapy. Although the appealing strategy for developing activatable PDT agents has been demonstrated to be an efficient way to control PDT selectivity to cancer cells while leaving normal cells unharmed, the construction of such an activatable photosensitizer requires judicious molecular design and is nontrivial.
13 The theranostic prodrug (TNP-SO) platform here was composed of a H 2 S-activated imaging probe, NIR-BSO and a light-sensitive drug, 3I-BOD. The two units were linked by a short diethylene glycolamine spacer. Interestingly, NIR-BSO displayed H 2 S-dependent NIR emission light up, thus enabling the selective detection of H 2 S-rich cancer cells. More importantly, such cancer imaging precisely directed when and where to implement the light illumination of 3I-BOD to produce cytotoxic ROS for on-demand cancer therapy, thus maximizing the therapeutic efficiency and minimizing side effects.
Results and discussion
The target compound TNP-SO was readily synthesized in a sequence of steps, as illustrated in Schemes 1 and S1. † The light-sensitive drug 3I-BOD was modied with compound 3 to afford 4 with the requisite cyanoacetamide function, which was incorporated into p-thiocresol substituted BODIPY via a Knoevenagel condensation reaction with aldehyde BODIPY 5, 14 thus affording an intermediate 6. Finally, conversion of a thioether unit with m-CPBA to a sulfoxide functional group produced the target theranostic prodrug TNP-SO in good yield. The identity and purity of all new compounds were veried by NMR and mass spectrometry.
It is known that elevated H 2 S production is closely related to various cancers, such as ovarian, breast, and colorectal cancers.
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Accordingly, H 2 S-activated NIR emissions could provide a powerful tool for the accurate identication of these cancers. We rst investigated the capability of TNP-SO as an activatable uorescent probe toward H 2 S under physiological conditions (CH 3 CN/PBS, 1 : 1, v/v, 20 mM, pH 7.4 , and room temperature). As shown in Fig. 1 , TNP-SO showed a mild absorption and a strong absorption with maxima at 500 and 533 nm, corresponding to NIR-BSO and 3I-BOD, respectively. Notably, the absorption of 3I-BOD partially obscures that of NIR-BSO owing to spectral overlap. Upon the treatment with 100 mM H 2 S, the absorption band at 500 nm decreased obviously accompanied by the emergence of a new absorption band around 655 nm, affording a dramatic red-shi of 155 nm. More importantly, this process activated a robust NIR uorescence at 712 nm that produced about 137-fold enhancement upon excitation at 640 nm. Such optical changes were ascribed to the conversion of TNP-SO into corresponding TNP-HS, proven by HRMS analysis (Fig. S1 †) . Collectively, TNP-SO exhibited H 2 S-triggered NIR emission light up, and thus preferable for in vivo visualization of H 2 S-rich cancers due to the deep penetration ability, minimal tissue absorption and low background autouorescence in the NIR region.
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The photosensitizing generation of 17 It was found that TNP-SO showed a relatively high singlet-oxygen yield (FD ¼ 49%) because of the heavy atom effect that facilitates intersystem crossing (ISC) of the excited energy ( Fig. S2 †) . Notably, the formation of TNP-SH had minimal effect on the production efficiency of 1 O 2 . Therefore, the theranostic TNP-SO would be suitable for imaging-guided on-demand administration of photodynamic therapy of cancers expressing elevated levels of H 2 S.
In light of the low solubility of TNP-SO in aqueous solution, the nanoplatform Nano-TNP-SO was generated by encapsulating TNP-SO into the hydrophobic interior of water-dispersible silica nanocomposites according to a previously established method (Scheme 2).
18 The loading efficiency of TNP-SO was determined with UV/vis absorbance spectra to be 0.96 wt%. Characterization of the resulting Nano-TNP-SO was performed by dynamic light scattering (DLS) and transmission electron microscopy (TEM) (Scheme 2), which showed that the hydrodynamic diameter of Nano-TNP-SO remained at 98 nm and negligible aggregation was observed in aqueous solutions for days (Fig. S3 †) .
Next, the photophysical response of Nano-TNP-SO toward H 2 S was evaluated in PBS buffer solutions (pH 7.4). As shown in Fig. 2 , the absorption maxima at 509 and 537 nm of NIR-BSO and 3I-BOD in silica nanocomposites showed a slightly bathochromic shi when compared to those in CH 3 CN/PBS. Interestingly, H 2 S-induced dramatic optical changes remained aer the encapsulation of TNP-SO. The addition of NaHS elicited the generation of the NIR absorption at 677 nm and reduction of the absorption at 509 nm (Fig. 2a) . Specically, a signicant increase in the uorescence intensity at 712 nm was noted upon Scheme 1 Synthesis of the target compound TNP-SO. excitation at 640 nm (Fig. 2b) . Notably, the reaction time of 70 min between TNP-SO and H 2 S in CH 3 CN/PBS was relatively slow. In contrast, the reaction of TNP-SO with H 2 S in Nano-TNP-SO was markedly accelerated, reaching completion within 20 min (Fig. 2c) . Moreover, the NIR uorescence exhibited a linear increase with H 2 S concentration (0-20 mM), determining the detection limit to be 21 nM which indicates the high sensitivity of Nano-TNP-SO for the detection of H 2 S (Fig. 2d) . Minimal optical responsiveness was observed in the presence of biologically related reactive sulfur (RSS), oxygen (ROS), and nitrogen species (RNS), indicative of its high selectivity for H 2 S (Fig. 2e) . Importantly, Nano-TNP-SO could also act as a good photosensitizer for the production of 1 O 2 (FD ¼ 32%) in PBS upon exposure to 530 nm light ( Fig. 2f and S4 †) . In addition, Nano-TNP-SO exhibited good photostability (Fig. S5 †) in aqueous solution, a critical factor for biomedical applications. Taken together, these advantages, including H 2 S-activated NIR emission light-up and efficient 1 O 2 generation, make Nano-TNP-SO a promising tool for the identication of cancers and the subsequent imaging-directed on-demand administration of photodynamic anticancer therapy.
To explore the capability of Nano-TNP-SO as an imaging probe for guiding where to implement the light illumination of 3I-BOD to produce cytotoxic ROS, the ability to selectively visualize H 2 S-rich cancer cells was investigated. As shown in Fig. 3 , HCT116 cells that express high levels of H 2 S gave strong NIR uorescence signals upon incubation with Nano-TNP-SO for 1 h. The presence of a CBS inhibitor aminooxyacetic acid (AOAA) signicantly attenuated the uorescence image due to the inhibition of cellular generation of H 2 S. In contrast, increase of H 2 S levels via stimulation with an allosteric CBS activator S-adenosyl-L-methionine (SAM) led to much stronger uorescence. As expected, HepG2 cells with the minimized level of H 2 S afford weak NIR uorescence. AOAA and SAM also displayed a negligible effect on the uorescence images (Fig. 3a) . On this basis, it can be concluded that Nano-TNP-SO is selectively activated to light up NIR uorescence in H 2 S-rich cancer cells, thus facilitating the accurate administration of PDT. According to the aforementioned imaging result, the cytotoxicity of Nano-TNP-SO toward HCT116 cells was then studied in the absence and presence of 530 nm light irradiation. MTT assay clearly demonstrated that Nano-TNP-SO showed low cytotoxicity in the absence of light. In contrast, greater cell death was seen in the case of HCT116 cells upon simultaneous treatment with Nano-TNP-SO and light irradiation at 530 nm (100 mW cm À2 ) for 10 min (Fig. 3b) . The cell death induced by the Nano-TNP-SO mediated PDT was also evaluated using staining experiments with calcein acetoxymethyl ester/propidium iodide (calcein-AM/PI). As shown in Fig. 3c , treatment of cells with either Nano-TNP-SO or a 530 nm laser alone resulted in predominantly calcein AM-dependent green uorescence, whereas PI-positive red signals were noted in cells upon treatment with Nano-TNP-SO (TNP-SO 5 mM) plus a 530 nm laser. These imaging results further demonstrated the low dark cytotoxicity and high photocytotoxicity of Nano-TNP-SO. Costaining experiments were employed to identify the location of Nano-TNP-SO utilizing commercially available Mito-Tracker Green and Lyso-Tracker Green (Fig. S6 †) . It was found that H 2 Sactivated red uorescence from Nano-TNP-SO showed good overlap with green uorescence from Mito-Tracker Green or Lyso-Tracker Green, indicative of nonspecic intracellular localization. Inspired by the aforementioned promising results, in vivo imaging-guided on demand PDT was evaluated. As shown in Fig. 4, a HCT116 tumor-bearing mouse treated with Nano-TNP-SO displayed tumor-specic activation of NIR uorescence as early as 1 min post-injection, whereas injection of Nano-TNP-SO into the normal muscle gave weak uorescence. Region of interest measurements gave a NIR uorescence signal ratio between the tumor and the normal site of 1.9 (5 min), 2.3 (10 min), 2.2 (30 min) and 2.0 (60 min). In addition, such specic NIR uorescence signals in the tumor region were signicantly reduced upon the pretreatment of the tumor with aminooxyacetic acid (AOAA), a cystathionine-b-synthase (CBS) inhibitor. Since the overexpression of CBS contributes to increased H 2 S levels in colon cancer, the inhibition of CBS activity by AOAA attenuated H 2 S levels and thus led to the reduction of NIR uorescence signals (Fig. S7 †) . All these results indicated that Nano-TNP-SO can be specically lit up in H 2 Srich colorectal cancers, correspondingly identifying the spatial location of the PDT agent and the timing of implementation of the light illumination. We next assessed the PDT effect of Nano-TNP-SO on tumors in HCTT116 tumor-bearing mice. Aer intratumor administration of Nano-TNP-SO and light irradiation, tumor growth was remarkably suppressed (Fig. 4c) . As a control, minimal tumor growth inhibition was observed in mice treated with Nano-TNP-SO or laser exposure alone. The tumor inhibition efficiency of PDT was calculated to be around 82% at 10 d aer treatment (Fig. 4d) . The H&E staining analysis demonstrated that signicant cancer cell necrosis was noticed in the tumor section with both Nano-TNP-SO administration and light irradiation, indicative of high therapeutic efficiency toward the tumor cells by the PDT with Nano-TNP-SO. The tumor tissues in control groups including no treatment and treatment with a laser or Nano-TNP-SO alone showed indiscernible necrosis, suggesting that Nano-TNP-SO has negligible dark toxicity. In addition to no obvious changes of the body weights in mice with various treatments (Fig. 4e) , no noticeable organ damage was observed in mice using H&E stained images of major organs (heart, liver, spleen, lung, and kidney). These results clearly indicate the low toxic effect of PDT using Nano-TNP-SO.
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Conclusions
In conclusion, we have designed and synthesized a theranostic probe for activatable near-infrared emission-guided on-demand administration of PDT. The new obtained small molecule probe was encapsulated into the hydrophobic interior of silica nanocomposites for the fabrication of a nanoprobe with good aqueous solubility and photostability. This nanoprobe displayed H 2 S-dependent NIR emission light up, preferable for in vivo visualization of H 2 S-rich cancers. In addition, the nanoprobe could also act as a good photosensitizer for efficient production of 1 O 2 . By exploiting these advantages, we employed such a probe for in vivo PDT, which revealed that cancer imaging precisely directed where to implement the light illumination to produce cytotoxic ROS for on-demand cancer therapy, thus maximizing the therapeutic efficiency and minimizing side effects. We expect that our design approach could promote new advancements in the areas of cancer diagnosis and therapy.
Conflicts of interest
The authors declare no competing nancial interest.
